TGTX Tg Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TGTX

Price (delayed)

$40.55

Market cap

$6.21B

P/E Ratio

12.59

Dividend/share

N/A

EPS

$3.22

Enterprise value

$6.52B

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 76
Relative Valuation: Rel. Valuation: 74
Relative Profitability: Rel. Profitability: 98

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active ...

Highlights
The revenue has soared by 81% YoY and by 14% QoQ
Tg Therapeutics's gross profit has surged by 72% YoY and by 13% QoQ
The equity has surged by 146% year-on-year but it has declined by 10% since the previous quarter
TGTX's debt has soared by 198% YoY and by 198% QoQ
The gross margin has decreased by 4.9% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tgtherapeutics.com
Peers: ALKS NERV

Key stats

What are the main financial stats of TGTX

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
1.1%
1 week
4.46%
1 month
13.57%
1 year
9.49%
YTD
36.03%
QTD
22.07%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$700.35M
Gross profit
$581.67M
Operating income
$149.5M
Net income
$461.9M
Gross margin
83.1%
Net margin
66%
The operating income has soared by 150% YoY and by 21% from the previous quarter
The revenue has soared by 81% YoY and by 14% QoQ
Tg Therapeutics's gross profit has surged by 72% YoY and by 13% QoQ
Tg Therapeutics's operating margin has increased by 37% YoY and by 7% QoQ

Price vs fundamentals

How does TGTX's price correlate with its fundamentals

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
TGTX P/E details
P/E
12.59
P/B
11.1
P/S
8.36
EV/EBIT
43.46
EV/EBITDA
43.44
EV/Sales
9.3
The P/E is 58% lower than the last 4 quarters average of 29.9
Tg Therapeutics's EPS has increased by 3.9% QoQ
The equity has surged by 146% year-on-year but it has declined by 10% since the previous quarter
The P/B is 49% below the 5-year quarterly average of 21.5 and 5% below the last 4 quarters average of 11.6
The P/S is 97% below the 5-year quarterly average of 248.8 and 6% below the last 4 quarters average of 8.8
The revenue has soared by 81% YoY and by 14% QoQ

Efficiency

How efficient is Tg Therapeutics business performance
The ROA has contracted by 18% from the previous quarter
Tg Therapeutics's return on sales has increased by 18% YoY
TGTX's ROIC is down by 15% QoQ and by 3.6% YoY
The company's return on equity fell by 14% QoQ

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The total assets is 62% higher than the total liabilities
The total assets has soared by 133% YoY and by 44% QoQ
Tg Therapeutics's total liabilities has surged by 128% QoQ and by 125% YoY
TGTX's debt is 29% higher than its equity
TGTX's debt has soared by 198% YoY and by 198% QoQ
The equity has surged by 146% year-on-year but it has declined by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.